Results 161 to 170 of about 67,369 (315)

DESENSITIZATION TO PERTUZUMAB/TRASTUZUMAB/HYALURONIDASE-ZZXF IN A PATIENT WITH HYMENOPTERA ANAPHYLAXIS [PDF]

V. Saldana-Fraire, Laura Merino León, R. Estrada-Mendizabal, A. Gonzalez-Estrada, A. Canel Paredes   +4 more
openalex   +1 more source

Clinical Immunogenicity of rHuPH20, a Hyaluronidase Enabling Subcutaneous Drug Administration [PDF]

, 2015
Sanna Rosengren, Samuel S. Dychter, Marie A. Printz, Lei Huang, Richard I. Schiff, H. Schwarz, John McVey, Fred H. Drake, Dan Maneval, Don A. Kennard, G. J. Frost, Barry J. Sugarman, Douglas B. Muchmore   +12 more
openalex   +1 more source

Short term treatment of secondary lymphedema with hyaluronidase injections reduces mouse hindlimb lymphedema

, 2023
Farima Dalaei, Amar Bučan, Alexander Wiinholt, Mads Gustaf Jørgensen, Christian Rønn Hansen, Christina Baun, Svend Hvidsten, Eva Kildall Hejbøl, Henrik Daa Schrøder, Jens Ahm Sørensen   +9 more
openalex   +2 more sources

MRD‐negative conversion with daratumumab monotherapy in newly diagnosed multiple myeloma patients in ≥VGPR/MRD‐positive after first‐line therapy: Final analysis of the open‐label, single‐arm multicentric phase 2 trial DART4MM

British Journal of Haematology, EarlyView.
In newly diagnosed multiple myeloma patients in ≥Very Good Partial Remission (VGPR) after a first‐line therapy daratumumab as consolidation/maintenance improved long‐term minimal residual disease negativity. Summary Daratumumab is approved for front‐line and relapsed myeloma therapy.
Alessandro Gozzetti, Paola Pacelli, Federico Caroni, Donatella Raspadori, Elena Bestoso, Elisabetta Antonioli, Gabriele Buda, Sara Ciofini, Adele Santoni, Luca Puccetti, Francesca Bacchiarri, Ludovica Pengue, Dania Tocci, Irene Attucci, Maria Livia del Giudice, Miriana Ruggieri, Alessandra Lombardo, Anna Marina Liberati, Veronica Candi, Vincenzo Sammartano, Alessandra Cartocci, Anna Sicuranza, Sara Galimberti, Alessandro Maria Vannucchi, Monica Bocchia   +24 more
wiley   +1 more source

HYALURONIDASE

British Journal of Anaesthesia, 1993
openaire   +2 more sources

Evaluation of Contribution of Nasunin to ORAC Value and Hyaluronidase Inhibitory Activity of Nasunin-containing Powder Obtained from Spent Eggplant Pre-pickling Solution

, 2017
Kazuko Itoh, Satomi Akutsu, Tsuneo Watanabe, Xiaonan Xie, Wataru Komatsu, Fumiaki Yoshizawa, Yasushi Uda   +6 more
openalex   +2 more sources

Comparative Pharmacokinetics and Insulin Action for Three Rapid-Acting Insulin Analogs Injected Subcutaneously With and Without Hyaluronidase [PDF]

, 2012
Linda Morrow, Douglas B. Muchmore, Marcus Hompesch, Elizabeth Ludington, Daniel E. Vaughn   +4 more
openalex   +1 more source

Study of the immunotoxic properties of pegylated hyaluronidase

, 2023
K.I. Ershov, A.M. Shvetsova, E. Yu. Sherstoboev, А. А. Чурин, В. В. Жданов, М. А. Korolev, П. Г. Мадонов   +6 more
openalex   +2 more sources

Unexpected Promotion of Bone Regeneration by Inhibition of BMPR1A‐Mediated BMP Signalling

Cell Proliferation, EarlyView.
BMPR1A downregulation reduces ID1, releases TCF3 to activate GNG4‐PI3K‐AKT signalling, thereby promoting OPC proliferation and bone regeneration. ABSTRACT Bone morphogenetic protein (BMP) signalling plays a pivotal role in bone regeneration by regulating osteoprogenitor cell (OPC) function, and BMPs have been widely used in clinical treatment. However,
Zihao Zhou, Yun Zhai, Xiaochen Liu, Jiaojiao Shao, Jiani Zhou, Zhaoyang Li, Jiale He, Shuxian Lin, Qi Zhang   +8 more
wiley   +1 more source

Referee report. For: Early hyaluronidase use in preventing skin necrosis after treatment with dermal fillers: Report of two cases [version 1; referees: 1 approved]

, 2018
Nicolò Bertozzi
openalex   +1 more source